T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Match Group
MTCH
|
+$3.17B |
| 2 |
Nike
NKE
|
+$1.94B |
| 3 |
Bank of America
BAC
|
+$1.84B |
| 4 |
FedEx
FDX
|
+$1.78B |
| 5 |
PNC Financial Services
PNC
|
+$1.61B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PPLI
People Inc
PPLI
|
+$4.1B |
| 2 |
Fortive
FTV
|
+$2.54B |
| 3 |
Linde
LIN
|
+$1.53B |
| 4 |
Alibaba
BABA
|
+$1.35B |
| 5 |
Willis Towers Watson
WTW
|
+$1.13B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.99% |
| 2 | Healthcare | 16.87% |
| 3 | Consumer Discretionary | 15.81% |
| 4 | Financials | 11.47% |
| 5 | Communication Services | 10.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BMY.RT
1301
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $9.67M | ﹤0.01% |
4,298,720
+591,511
| +16% | +$1.69M |
|
|
CNST
1302
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $9.59M | ﹤0.01% |
473,333
+199,294
| +73% | +$4.87M |
|
1303
Hain Celestial
HAIN
$52M
| $9.55M | ﹤0.01% |
278,425
+243,809
| +704% | +$8.08M |
|
1304
Kymera Therapeutics
KYMR
$9.57B
| $9.52M | ﹤0.01% |
+294,695
| New | +$9M |
|
1305
iShares Core S&P 500 ETF
IVV
$908B
| $9.49M | ﹤0.01% |
28,245
+3,228
| +13% | +$1.07M |
|
1306
Royal Gold
RGLD
$19.5B
| $9.46M | ﹤0.01% |
78,710
-6,760
| -8% | -$888K |
|
1307
Hamilton Lane
HLNE
$5.83B
| $9.36M | ﹤0.01% |
144,903
+39,581
| +38% | +$2.71M |
|
1308
Orchestra BioMed
OBIO
$260M
| $9.35M | ﹤0.01% |
+850,000
| New | +$9.54M |
|
1309
RenaissanceRe
RNR
$13.4B
| $9.34M | ﹤0.01% |
55,015
-53,503
| -49% | -$9.46M |
|
1310
Globant
GLOB
$1.61B
| $9.31M | ﹤0.01% |
51,935
-2,941
| -5% | -$506K |
|
|
VER
1311
DELISTED
VEREIT, Inc.
VER
| $9.28M | ﹤0.01% |
285,592
-59,249
| -17% | -$1.95M |
|
1312
FRP Holdings
FRPH
$425M
| $9.25M | ﹤0.01% |
444,002
-1,800
| -0.4% | -$36.9K |
|
1313
VanEck Fallen Angel High Yield Bond ETF
ANGL
$3.11B
| $9.06M | ﹤0.01% |
+304,600
| New | +$9.13M |
|
1314
Invitation Homes
INVH
$18.1B
| $8.95M | ﹤0.01% |
319,614
-1,083
| -0.3% | -$30.9K |
|
1315
Universal Insurance Holdings
UVE
$1.19B
| $8.93M | ﹤0.01% |
644,927
-142,842
| -18% | -$2.52M |
|
1316
Lemonade
LMND
$4.09B
| $8.87M | ﹤0.01% |
+178,388
| New | +$11.2M |
|
1317
Kimco Realty
KIM
$16.4B
| $8.86M | ﹤0.01% |
787,032
-7,229
| -0.9% | -$85.3K |
|
1318
ON Semiconductor
ON
$31.9B
| $8.68M | ﹤0.01% |
400,105
-96,128
| -19% | -$2.04M |
|
1319
Markel Group
MKL
$22.8B
| $8.65M | ﹤0.01% |
8,882
-1,235
| -12% | -$1.25M |
|
1320
Ironwood Pharmaceuticals
IRWD
$691M
| $8.64M | ﹤0.01% |
960,158
-64,134
| -6% | -$637K |
|
1321
Pinterest
PINS
$13.6B
| $8.61M | ﹤0.01% |
207,364
-1,222,267
| -85% | -$39.9M |
|
1322
Zions Bancorporation
ZION
$10.5B
| $8.58M | ﹤0.01% |
293,646
-19,198
| -6% | -$619K |
|
1323
Wave Life Sciences
WVE
$1.04B
| $8.49M | ﹤0.01% |
999,918
-319,064
| -24% | -$3.5M |
|
1324
Invesco
IVZ
$14.3B
| $8.48M | ﹤0.01% |
743,177
+37,271
| +5% | +$395K |
|
1325
ALX Oncology
ALXO
$275M
| $8.44M | ﹤0.01% |
+223,654
| New | +$8.79M |
|
Similar funds
T. Rowe Price Associates's Q3 2020 Portfolio in Review
As of Q3 2020, T. Rowe Price Associates held 2,679 positions worth $864B, up 8.7% from $795B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q3 2020 filing shows 185 new, 873 increased, 1,330 reduced and 90 closed positions. Its largest new stake was nCino: 5,133,240 shares worth $395M. The largest sale was People Inc, an estimated $4.1B.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q3 2020 buy was nCino: 5,133,240 shares worth $395M.
- T. Rowe Price Associates added most to Match Group in Q3 2020, an estimated $3.17B increase.
- T. Rowe Price Associates's biggest Q3 2020 reduction was People Inc, cutting an estimated $4.1B.
- T. Rowe Price Associates fully exited 58.com Inc in Q3 2020, selling an estimated $468M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $864B portfolio in Q3 2020.
- T. Rowe Price Associates opened 185 new positions and closed 90 in Q3 2020.
- T. Rowe Price Associates's portfolio value rose 8.7% quarter-over-quarter to $864B.
Based on T. Rowe Price Associates's 13F filing for Q3 2020, filed 16 Nov 2020.